Elpiscience (Suzhou) Biopharma, Ltd.
π¨π³China
- Country
- π¨π³China
- Ownership
- Private, Subsidiary
- Established
- 2018-03-20
- Employees
- -
- Market Cap
- -
- Website
- https://cn.elpiscience.com
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06623136
- Locations
- π¨π³
Taizhou Hospital, Taizhou, China
π¨π³Jilin Cancer Hospital, Changchun, Jilin, China
π¨π³The First Affiliated Hospital of He'nan University of Science and Technology, Luoyang, China
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
Phase 1
Recruiting
- Conditions
- Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05717348
- Locations
- π¨π³
Shanghai Chest Hospital, Shanghai, China
A Study of ES104 in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05167448
- Locations
- π¨π³
Beijing Cancer Hospital, Beijing, China
Β© Copyright 2025. All Rights Reserved by MedPath